• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >'Price management' and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.
【24h】

'Price management' and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.

机译：“价格管理”及其对医院的影响药品支出和可用性医院的药品在新西兰。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: In 2002, the Pharmaceutical Management Agency (PHARMAC) began negotiating new price contracts for 90% of hospital pharmaceuticals on behalf of all New Zealand (NZ) public hospitals ("price management"[PM]). The present study was undertaken to examine the impact of 3 years of PM on hospital pharmaceutical expenditure, and the impact of the new contracts on the availability of medicines. METHODS: Annual savings for 29 major public hospitals (financial years 2003/4 to 2005/6) were calculated from the data from 11 hospitals and data from PHARMAC. Inpatient and total hospital pharmaceutical expenditure (IPE, THPE) (2000/1 to 2005/6) were calculated from the data from 23 hospitals. Hospital pharmaceutical expenditure (2000/1 to 2005/6) was compared with community pharmaceutical expenditure (CPE) in NZ, and with THPE in the UK, Canada, Norway, and Sweden. Surveys were undertaken (2004, 2005) to examine any changes in medicine availability resulting from the new contracts. RESULTS: Annual savings were NZDollars 7.84 million (m) to NZDollars 13.45m (2003/4 to 2005/6). Growth in IPE slowed for all hospitals in 2003 to 2004. Mean growth was higher for IPE and THPE than for CPE (8.8%, 9.7% vs. 1.9%). Mean growth in THPE appeared slightly lower in NZ (9.6%) and Norway (7.3%) than in the UK 14%, Sweden 12.5%, or Canada 10.2%. Some availability problems occurred with new contract items ("out-of-stocks"; products perceived as inferior). Problems were usually resolved in weeks, but some took more than a year. CONCLUSION: PM was moderately successful saving NZDollars 8m to NZDollars 13m (6-8%) in 2003/4 to 2005/6 and slowing growth in IPE in 2003/4. Further research should examine whether the favorable economic effects can be sustained while unfavorable effects are minimized.
机译：目标:2002年,药品管理机构(医药)开始协商新价格合同医院药品的90%代表所有的新西兰(新西兰)公立医院(“价格管理”[点])。进行检查的影响点的3年在医院药品支出,新合同的可用性的影响的药物。主要的公立医院(金融年重提从11 2005/6)计算的数据医院和医药的数据。医院药品总支出(IPE这个)(2000/1到2005/6)计算的数据来自23个医院。支出(2000/1到2005/6)相比社区药品支出(CPE)在新西兰,这个在英国,加拿大,挪威和瑞典。检验医学的任何变化的可用性产生的新合同。储蓄NZDollars 784万(m)NZDollars 13.45(2005/6)重提。IPE放缓对所有医院从2003年到2004年。IPE和这个意味着增长高于CPE(8.8%、9.7%和1.9%)。出现在新西兰略低(9.6%)和挪威在英国(7.3%)高于14%,瑞典12.5%,或加拿大10.2%。与新合同项(“缺货”;产品视为劣质)。通常在几周内解决,但一些了比一年。成功保存NZDollars 8 m NZDollars 13米(6 - 8%)重提2005/6和经济增长放缓IPE重提。是否可以有利的经济影响持续的不利影响最小化。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号